Mounting evidence from both clinical trials and observational studies show increased awareness on both treatment outcomes in ANCA-vasculitis (AAV) patients but also on disease and especially treatment complications. Alongside these topics in the last two years there is as well an increased interest in patient quality of life and frailty as measures of both disease activity as well as of potential treatment success as well as complications. AAVs papers are rarely focused on aforementioned topics compared to treatment trials and biomarker studies. Patient input, as stakeholders, seems to play increased role in both treatment trials as well as treatment guidelines (recommendations for plasma exchange therapy as an example). That makes studying quality of life and patient frailty an important topic. Summary: studying every aspect of AAVs makes important addition to further understanding disease and providing better care for patients.

In this research topic I would like to put an emphasis on clinical outcomes in AAV patients, both in terms of disease outcomes but also in terms of treatment complications such as infections, cardiovascular complications and malignancies. Biomarkers of diseases activity as well as outcome predictors are interesting as well because we still use clinical presentations and standard laboratory tests to assess disease activity. Last but not least I feel more emphasis has to be not only on clinical and laboratory outcomes but also on patient quality of life including also initial patient presentation such as frailty which I believe influences treatment options as well as complications and outcomes.

This Research Topic accepts Original Research, Systematic Review, Review, Clinical Trial and Brief Research Report. We welcome manuscripts focusing on, but not limited to, the following sub-topics:

• Clinical outcomes in ANCA vasculitis patients
• Biomarkers in ANCA vasculitis
• Treatment and disease complications in ANCA vasculitis patients (including infectious complications, cardiovascular complications and malignancies)
• Patient frailty and quality of life

Topic Editor Giacomo Emmi receives financial support for consultancy and advisory board from Gsk, AstraZeneca, Sobi, Novartis, Vifor, and Boheringer. The other Topic Editors declare no competing interests with regard to the Research Topic subject.

Submit your idea

Impact

Frontiers in Immunology

Participating Journals

Submit your idea

Impact